NASDAQ: ELUTElutia Inc Stock
$2.89+0.02 (+0.7%)
Updated Apr 24, 2024
ELUT Price
$2.89
Fair Value Price
N/A
Market Cap
$70.15M
52 Week Low
$1.10
52 Week High
$4.19
P/E
-1.4x
P/B
-1.82x
P/S
1.59x
PEG
N/A
Dividend Yield
N/A
Revenue
$24.75M
Earnings
-$37.66M
Gross Margin
44.7%
Operating Margin
-128.64%
Profit Margin
-152.2%
Debt to Equity
-2.13
Operating Cash Flow
-$22M
Beta
0.09
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ELUT Overview
Aziyo Biologics, Inc. develops regenerative medical products for the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. Tthe company also provides contract manufacturing services for various products to corporate customers. The company was incorporated in 2015 and is headquartered in Silver Spring, MD.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ELUT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ELUT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ELUT is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
ELUT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more ELUT due diligence checks available for Premium users.
Be the first to know about important ELUT news, forecast changes, insider trades & much more!
ELUT News
Valuation
ELUT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.4x
Industry
30.46x
Market
41.27x
ELUT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.82x
Industry
3.73x
ELUT's financial health
Profit margin
Revenue
$5.9M
Net Income
-$9.3M
Profit Margin
-158.5%
ELUT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ELUT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$43.4M
Liabilities
$82.0M
Debt to equity
-2.13
ELUT's short-term liabilities ($43.04M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ELUT's long-term liabilities ($38.99M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ELUT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ELUT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.1M
Investing
$14.5M
Financing
-$695.0k
ELUT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ELUT vs Medical Device Stocks
Elutia Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.